Nuwellis (NASDAQ:NUWE – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Zacks.com reports. The firm presently has a $0.75 price target on the stock. Zacks Investment Research‘s price target indicates a potential upside of 7.67% from the company’s current price.
According to Zacks, “Nuwellis Inc. is a medical device company. It is focused on developing, manufacturing and commercializing the Aquadex SmartFlow(R) System for ultrafiltration therapy. Nuwellis Inc., formerly known as CHF Solutions, is headquartered in Minneapolis, Minn. “
Shares of NASDAQ:NUWE opened at $0.70 on Thursday. The stock has a market capitalization of $7.34 million, a price-to-earnings ratio of -0.30 and a beta of 0.90. Nuwellis has a 1-year low of $0.55 and a 1-year high of $5.30. The company’s fifty day moving average is $0.78 and its two-hundred day moving average is $1.02.
Nuwellis Company Profile (Get Rating)
Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.
- Get a free copy of the StockNews.com research report on Nuwellis (NUWE)
- It’s Time To Get Interested In Ethereum Again
- Stratasys Stock Forming a Tradeable Bottom
- How to Invest in Water Stocks: A Tutorial for Investors
- Expedia Group: Recovering with the Travel Industry
- It’s Time To Grab The Lovesac Company By The Shorts
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.